Pretreatment nomogram that predicts 5-year probability of @entity3 following three-dimensional conformal radiation therapy for XXXX .

@entity1 @entity263 @entity3 @entity1486
PURPOSE: There are several nomograms for the @entity1 considering radiation therapy for clinically @entity263 . Because of the questionable clinical implications of @entity1486 recurrence, its use as an end point has been criticized in several of these nomograms. The goal of this study was to create and to externally validate a nomogram for predicting the probability that a @entity1 will develop @entity3 within 5 years after three-dimensional conformal radiation therapy (CRT). @entity1 AND METHODS: We conducted a retrospective, nonrandomized analysis of 1,677 @entity1 treated with three-dimensional CRT at Memorial Sloan-Kettering Cancer Center (MSKCC) from 1988 to 2000. Clinical parameters examined were pretreatment @entity1486 level, clinical stage, and biopsy Gleason sum. @entity1 were followed until their deaths, and the time at which they developed @entity3 was noted. A nomogram for predicting the 5-year probability of developing @entity3 was constructed from the MSKCC cohort and validated using the Cleveland Clinic series of 1,626 @entity1 . RESULTS: After three-dimensional CRT, 159 @entity1 developed @entity3 . At 5 years, 11% of @entity1 experienced @entity3 by cumulative incidence analysis (95% CI, 9% to 13%). A nomogram constructed from the data gathered from these @entity1 showed an excellent ability to discriminate among @entity1 in an external validation data set, as shown by a concordance index of 0.81. CONCLUSION: A nomogram with reasonable accuracy and discrimination has been constructed and validated using an external data set to predict the probability that a @entity1 will experience @entity3 within 5 years after three-dimensional CRT.
